Live Webinar – Preparing for JCA: Evidence, pricing, and launch strategy in a changing European access landscape
How should global and European market access teams prepare for JCA while managing national HTA requirements, evidence uncertainty, and pricing pressure? What can early experience with JCA tell us about evidence planning, PICO prediction, and launch sequencing?
The EU Health Technology Assessment Regulation is reshaping how clinical evidence is assessed across Europe. With JCA now underway for oncology medicines and advanced therapy medicinal products, companies need to prepare earlier, align global and regional evidence plans, and understand how EU-level clinical assessment will sit alongside national appraisal, pricing, and reimbursement processes.
We invite you to join us on Tuesday 6th October 2026, 10:30–11:30am BST/11:30am–12:30pm CET for a Petauri Evidence webinar designed to help global and European market access teams prepare for JCA and the wider value–evidence–price challenge.
In this session, Adam will be joined by a panel of Petauri Evidence experts spanning market access strategy, HTA, evidence generation, and pricing and value communication. Together, they will share practical lessons from early JCA implementation and discuss how companies can prepare for the evolving European access landscape.
The discussion will focus on what companies can do now to reduce risk, make earlier strategic decisions, and align global, European, and local teams around a practical roadmap from early strategy through to dossier development and launch roll-out.
In this webinar, we will explore:
- What early JCA experience indicates about PICO scoping, evidence expectations, and dossier planning
- How to balance EU-level JCA requirements with national HTA submissions, cost-effectiveness analysis, budget impact work, and payer negotiations
- Evidence generation challenges, including indirect treatment comparisons, real-world evidence, uncertainty, and transferability across markets
- How national HTA bodies may use JCA reports and where local market divergence is likely to persist
- Launch sequencing and pricing considerations in the context of MFN, international reference pricing, and cross-market price dynamics
- Practical steps for building a value–evidence–price roadmap across global, European, and local teams
We invite you to put your questions to our panel in this session. Please suggest a question when you register.
If you cannot attend the webinar live, please register nonetheless, as all registrants will receive a recording of the webinar.
The webinar is free and open to all market access, HEOR, strategic, commercial, and evidence generation teams in Pharmaceutical, Medtech, and Diagnostics companies. We also welcome attendees from healthcare systems. Some colleagues from other organisations may attend at the discretion of Petauri Evidence
Share